Dynavax Technologies Corporation news

   Watch this stock
Showing stories 1 - 10 of about 10   

Articles published

DVAX 23.86 +0.39 (1.66%)
price chart
Analysts At William Blair Maintain Outperform On Dynavax Technologies
The firm points out that Dynavax has received the briefing book from the FDA by now and no news so far is good news. Moreover, Dynavax had communicated that if there were material information, the company would disclose it to the public. The firm ...
Dynavax Gets Crushed After Advisory Committee Vote
Assuming that the FDA decision turns out to be no (a favorable bet), we can still infer that Dynavax will conduct additional safety studies that can be included in Heplislav's next BLA.
Dynavax Falls After Vaccine Fails to Win Panel Backing  Bloomberg
Dynavax's Heplisav Vaccine Works on Hepatitis B, FDA Says
Nov. 13 (Bloomberg) -- Dynavax Technologies Corp.'s Heplisav vaccine works against the contagious liver disease hepatitis B, Food and Drug Administration staff said.
Why Dynavax's HEPLISAV Is Likely To Be Approved: Impact On Future Vaccine ...
Dynavax's (NASDAQ:DVAX) HEPLISAV had an FDA Advisory Committee on November 15, 2012. The Advisory Committee voted 13 to one that HEPLISAV data adequately demonstrated immunogenicity.
New Virus on the Block: Investing for Flu Season
Dynavax Technologies Corporation (DVAX, Earnings, Analysts, Financials): Dynavax Technologies Corporation, a clinical-stage biopharmaceutical company, discovers and develops novel products to prevent and treat infectious diseases.
Can Dynavax overcome Heplisav blow?
Two weeks ago, an FDA panel dealt a blow to Dynavax Technologies ($DVAX), raising concerns about the safety of the company's hepatitis B vaccine, Heplisav. Shares dropped and investors tend to turn their backs on a company when stock prices go down.
European Stocks Drop; Yen Weakens to Six-Month Low
Dynavax Technologies Corp. slid 47 percent after its hepatitis B vaccine failed to win the backing of U.S. regulatory advisers.
Invest like Warren Buffett with These ETFs
Obviously, this can be easily replicated by any other insurance company, suggesting that a broad look at the space, in order to diversify away risk if there is a catastrophe, could be the way to go.
JA Solar Has to Stoop to a Reverse Stock Split
What you are about to read is a sneaky way of announcing a reverse stock split to stay within the listing standards of the $1.00 share price rule.
Weekend trade centre planned for Walker Road
Encana Corp to sell its Denver Julesberg basin assets for $900 million. Encana ... Thanks to an updated filing this week, the stage has been set for another initial public offering by a Canadian technology company. ... Webinar Presented by Precision ...